Mara Goldstein
Stock Analyst at Mizuho
(2.55)
# 2,320
Out of 5,182 analysts
70
Total ratings
48.08%
Success rate
13.71%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mara Goldstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Maintains: Outperform | $30 → $25 | $8.82 | +183.45% | 4 | Mar 24, 2026 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $30 → $10 | $3.32 | +201.20% | 5 | May 12, 2025 | |
| VSTM Verastem | Maintains: Outperform | $9 → $8 | $5.45 | +46.79% | 7 | Apr 9, 2025 | |
| RCUS Arcus Biosciences | Maintains: Buy | $51 → $42 | $22.07 | +90.30% | 4 | Jan 30, 2024 | |
| XNCR Xencor | Maintains: Buy | $59 → $50 | $12.31 | +306.17% | 2 | Jan 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $45 | $24.64 | +82.63% | 1 | Dec 22, 2023 | |
| INCY Incyte | Maintains: Neutral | $82 → $77 | $93.69 | -17.81% | 5 | Dec 14, 2023 | |
| ERAS Erasca | Maintains: Buy | $8 → $7 | $17.06 | -58.97% | 3 | Nov 29, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $12 → $8 | $1.15 | +595.65% | 5 | Nov 20, 2023 | |
| NKTR Nektar Therapeutics | Reiterates: Neutral | $90 | $76.24 | +18.05% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.5 | $14.35 | -75.61% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $1.43 | +25,074.83% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 → $20 | $5.23 | +282.41% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $130 | $119.28 | +8.99% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $2 | $4.30 | -53.49% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $12 | $1.36 | +782.35% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 → $20 | $65.48 | -69.46% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $48 | $6.83 | +602.78% | 5 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $31.35 | - | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $5.95 | +135.29% | 1 | Oct 12, 2017 |
Kura Oncology
Mar 24, 2026
Maintains: Outperform
Price Target: $30 → $25
Current: $8.82
Upside: +183.45%
Iovance Biotherapeutics
May 12, 2025
Maintains: Outperform
Price Target: $30 → $10
Current: $3.32
Upside: +201.20%
Verastem
Apr 9, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $5.45
Upside: +46.79%
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51 → $42
Current: $22.07
Upside: +90.30%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59 → $50
Current: $12.31
Upside: +306.17%
Syndax Pharmaceuticals
Dec 22, 2023
Initiates: Buy
Price Target: $45
Current: $24.64
Upside: +82.63%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82 → $77
Current: $93.69
Upside: -17.81%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8 → $7
Current: $17.06
Upside: -58.97%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12 → $8
Current: $1.15
Upside: +595.65%
Nektar Therapeutics
Aug 7, 2023
Reiterates: Neutral
Price Target: $90
Current: $76.24
Upside: +18.05%
Jun 16, 2023
Reiterates: Neutral
Price Target: $3.5
Current: $14.35
Upside: -75.61%
Apr 24, 2023
Reiterates: Buy
Price Target: $360
Current: $1.43
Upside: +25,074.83%
Apr 19, 2023
Upgrades: Buy
Price Target: $10 → $20
Current: $5.23
Upside: +282.41%
Apr 10, 2023
Reiterates: Buy
Price Target: $130
Current: $119.28
Upside: +8.99%
Mar 28, 2023
Maintains: Neutral
Price Target: $4 → $2
Current: $4.30
Upside: -53.49%
Mar 8, 2023
Maintains: Buy
Price Target: $18 → $12
Current: $1.36
Upside: +782.35%
Sep 6, 2019
Reiterates: Overweight
Price Target: $14 → $20
Current: $65.48
Upside: -69.46%
Jul 8, 2019
Downgrades: Neutral
Price Target: $34 → $48
Current: $6.83
Upside: +602.78%
Apr 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $31.35
Upside: -
Oct 12, 2017
Maintains: Overweight
Price Target: $12 → $14
Current: $5.95
Upside: +135.29%